ECSP17084331A - Formulaciones farmacéuticas - Google Patents

Formulaciones farmacéuticas

Info

Publication number
ECSP17084331A
ECSP17084331A ECIEPI201784331A ECPI201784331A ECSP17084331A EC SP17084331 A ECSP17084331 A EC SP17084331A EC IEPI201784331 A ECIEPI201784331 A EC IEPI201784331A EC PI201784331 A ECPI201784331 A EC PI201784331A EC SP17084331 A ECSP17084331 A EC SP17084331A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical formulations
pharmaceutically acceptable
acceptable salt
emtricitabine
dosage form
Prior art date
Application number
ECIEPI201784331A
Other languages
English (en)
Inventor
Joanna Koziara
Scott Mccallister
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56418608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17084331(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of ECSP17084331A publication Critical patent/ECSP17084331A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona una forma de dosificación oral sólida que comprende alafenamida de tenofovir o una sal farmacéuticamente aceptable de la misma, y emtricitabina o una sal farmacéuticamente aceptable de la misma.
ECIEPI201784331A 2015-06-30 2017-12-21 Formulaciones farmacéuticas ECSP17084331A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562187113P 2015-06-30 2015-06-30
US201662298373P 2016-02-22 2016-02-22
US201662301429P 2016-02-29 2016-02-29
US201662317286P 2016-04-01 2016-04-01

Publications (1)

Publication Number Publication Date
ECSP17084331A true ECSP17084331A (es) 2018-01-31

Family

ID=56418608

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201784331A ECSP17084331A (es) 2015-06-30 2017-12-21 Formulaciones farmacéuticas

Country Status (26)

Country Link
US (3) US20180177734A1 (es)
EP (6) EP4527467B1 (es)
JP (3) JP6667556B2 (es)
KR (2) KR102313668B1 (es)
CN (2) CN107847450A (es)
AU (3) AU2016287500B2 (es)
BR (1) BR112017027843A2 (es)
CA (1) CA2990210C (es)
CL (1) CL2017003320A1 (es)
CO (1) CO2017013293A2 (es)
CU (1) CU20170168A7 (es)
DO (1) DOP2017000306A (es)
EA (1) EA201792592A1 (es)
EC (1) ECSP17084331A (es)
ES (5) ES3007987T3 (es)
HK (1) HK1248547A1 (es)
IL (1) IL256364A (es)
MA (1) MA50541A (es)
MX (1) MX2017016806A (es)
PE (1) PE20180411A1 (es)
PH (1) PH12017502431A1 (es)
PL (5) PL4070788T3 (es)
PT (4) PT4070788T (es)
SI (4) SI3607939T1 (es)
SV (1) SV2017005601A (es)
WO (1) WO2017004244A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
WO2017083304A1 (en) 2015-11-09 2017-05-18 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
CN116730920A (zh) 2017-02-17 2023-09-12 文涵治疗有限公司 Ag-10的制备方法、其中间体及其盐
WO2018153977A1 (en) * 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
AU2018239257B2 (en) * 2017-03-20 2023-09-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV post-exposure prophylaxis
RU2662160C9 (ru) 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
TWI817999B (zh) 2018-03-23 2023-10-11 美商文涵治療有限公司 使用ag10治療ttr澱粉樣沉積症之方法
SI3836920T1 (sl) * 2018-08-17 2026-02-27 Eidos Therapeutics, Inc. Formulacije AG10
CN111096954B (zh) * 2018-10-29 2022-09-16 江苏豪森药业集团有限公司 一种用于抗病毒感染的药物组合物及制备方法
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
CN110251476B (zh) * 2019-08-01 2022-08-09 海思科制药(眉山)有限公司 一种恩曲他滨替诺福韦药物组合物
CN110917197A (zh) * 2019-12-31 2020-03-27 常州恒邦药业有限公司 一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法
TWI728709B (zh) * 2020-02-19 2021-05-21 台灣森本生物科技開發股份有限公司 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
CN117653644A (zh) * 2022-08-24 2024-03-08 安徽贝克制药股份有限公司 包含恩曲他滨、替诺福韦和利匹韦林的药物组合物
WO2024211882A1 (en) * 2023-04-07 2024-10-10 Navinta, Llc Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents
CN117338733B (zh) * 2023-10-12 2024-05-28 杭州和泽坤元药业有限公司 一种富马酸替诺福韦二吡呋酯片及其制备工艺
WO2025229473A1 (en) * 2024-05-01 2025-11-06 Lupin Limited Tenofovir alafenamide compositions
CN119174735A (zh) * 2024-09-03 2024-12-24 安徽贝克生物制药有限公司 一种含利匹韦林的复方片及制备方法
CN119139247A (zh) * 2024-09-05 2024-12-17 安徽贝克生物制药有限公司 一种恩曲他滨丙酚替诺福韦复方片及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119443A1 (en) 2000-07-21 2002-08-29 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP2393485B1 (en) 2009-02-06 2015-07-29 Gilead Sciences, Inc. Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir
ES2608871T5 (es) 2011-08-16 2024-04-04 Gilead Sciences Inc Alafenamide hemifumarate de tenofovir
AU2013204727A1 (en) 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
JP2016528240A (ja) * 2013-08-14 2016-09-15 ラシオファルム ゲーエムベーハー ドルテグラビル、エムトリシタビン及びテノホビルの医薬コンビネーションを有する医薬
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
NO2717902T3 (es) * 2014-06-20 2018-06-23

Also Published As

Publication number Publication date
KR102121329B1 (ko) 2020-06-17
MX2017016806A (es) 2018-05-07
PL4070787T3 (pl) 2023-07-24
PL3607939T3 (pl) 2022-11-07
PL3316868T3 (pl) 2020-10-19
PT4070787T (pt) 2023-05-22
MA50541A (fr) 2021-04-07
EA201792592A1 (ru) 2018-06-29
CA2990210A1 (en) 2017-01-05
EP3607939A1 (en) 2020-02-12
PH12017502431A1 (en) 2018-07-02
CN119606990A (zh) 2025-03-14
US20170000807A1 (en) 2017-01-05
PT4070788T (pt) 2023-06-06
KR20200067937A (ko) 2020-06-12
EP4527467A3 (en) 2025-05-21
US20180177734A1 (en) 2018-06-28
EP4070787A1 (en) 2022-10-12
EP4233846B1 (en) 2024-12-04
SV2017005601A (es) 2018-05-04
JP2018519297A (ja) 2018-07-19
HK1248547A1 (zh) 2018-10-19
JP6978534B2 (ja) 2021-12-08
EP4233846A3 (en) 2023-10-04
IL256364A (en) 2018-02-28
BR112017027843A2 (pt) 2018-09-04
ES2925246T3 (es) 2022-10-14
JP2020079304A (ja) 2020-05-28
EP4527467B1 (en) 2026-03-18
JP2021185188A (ja) 2021-12-09
US20250281412A1 (en) 2025-09-11
CU20170168A7 (es) 2018-07-05
WO2017004244A1 (en) 2017-01-05
AU2019210558A1 (en) 2019-08-15
EP4233846C0 (en) 2024-12-04
ES2786549T3 (es) 2020-10-13
PT3316868T (pt) 2020-04-21
CA2990210C (en) 2021-01-12
ES2945896T3 (es) 2023-07-10
EP4070787B1 (en) 2023-03-01
ES3007987T3 (en) 2025-03-21
SI3607939T1 (sl) 2022-10-28
AU2021202009A1 (en) 2021-04-29
EP4233846A2 (en) 2023-08-30
EP4070788B1 (en) 2023-03-22
PL4233846T3 (pl) 2025-03-24
CN107847450A (zh) 2018-03-27
AU2021202009B2 (en) 2023-04-13
AU2016287500A1 (en) 2018-01-18
DOP2017000306A (es) 2018-01-15
ES2945345T3 (es) 2023-06-30
CL2017003320A1 (es) 2018-07-13
PL4070788T3 (pl) 2023-07-10
EP4527467A2 (en) 2025-03-26
EP3316868A1 (en) 2018-05-09
EP3607939B1 (en) 2022-06-01
AU2019210558B2 (en) 2021-04-22
JP6667556B2 (ja) 2020-03-18
EP3316868B1 (en) 2020-02-19
EP4070788A1 (en) 2022-10-12
SI4070788T1 (sl) 2023-06-30
KR20180021134A (ko) 2018-02-28
SI4070787T1 (sl) 2023-07-31
KR102313668B1 (ko) 2021-10-19
PT3607939T (pt) 2022-09-12
SI3316868T1 (sl) 2020-04-30
AU2016287500B2 (en) 2019-05-02
CO2017013293A2 (es) 2018-05-31
PE20180411A1 (es) 2018-03-01

Similar Documents

Publication Publication Date Title
ECSP17084331A (es) Formulaciones farmacéuticas
EP4045480A4 (en) PHARMACEUTICAL FORMULATIONS
IL264210A (en) High-strength oral cannabinoid dosage forms
MX2017016802A (es) Formulaciones farmaceuticas.
IL258464A (en) Pharmaceutical compositions for oral administration of peptide drugs
IL264065A (en) Oral gastroretentive formulations and uses thes thereof
EP3541385A4 (en) PHARMACEUTICAL FORMULATIONS
PH12016501841A1 (en) Immunosuppressant formulation
HUP1700253A1 (hu) Szilárd orális gyógyszerkészítmények
MA55015A (fr) Formulations pharmaceutiques
ZA202006570B (en) Pharmaceutical formulations
EP3746080A4 (en) PHARMACEUTICAL FORMULATIONS
EP3383397A4 (en) PHARMACEUTICAL COMPOSITIONS WITH DORAVIRIN, TENOFOVIR DISOPROXIL FUMARATE AND LAMIVUDIN
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
EP3697393A4 (en) DOSAGE FORMS
SG11202010792TA (en) Improved pharmaceutical formulations
EP3651800C0 (en) HYDROCOMPRESSED PHARMACEUTICAL FORMULATIONS
EP3512507A4 (en) ORAL MEDICINAL FORMULATIONS
CR20170601A (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
ZA201804275B (en) Oral pharmaceutical composition comprising taste-masked n-acetylcysteine
JOP20170198A1 (ar) صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين
HUE056233T2 (hu) Ibuprofén készítmények közvetlen orális beadásra
CY1123966T1 (el) Διαδικασια για την παρασκευη νατριουχου εποπροστενολης ενισχυμενης σταθεροτητας